Scores are 0 to 100 against every US stock we track; 50 is average. Recomputed after every US market close.
Fiscal year to November 2025, from the company's annual filing with the SEC.
| Salesyearly sales | $84.0M |
| Sales growthchange from the year before | +54.0% |
| Operating marginshare of sales left after running the business | -340.2% |
| Net marginshare of sales kept as profit | -314.9% |
| Free-cash-flow marginspare cash generated per $100 of sales | -313.7% |
| Return on invested capitalprofit made on each $100 put into the business | -41.9% |
| Return on equityprofit vs. shareholders' accounting value | -49.1% |
| Change in share countnegative = the company is buying back its shares | +29.1% |
3 insiders sold $954K (74% under pre-arranged plans) on the open market.
| Hansen GwennChief Scientific Officer | Sold (plan)Aug 5 | 4,356 shat $25.00 · $109K |
| Hansen GwennChief Scientific Officer | Sold (plan)Aug 4 | 4,111 shat $24.36 · $100K |
| van Houte HansChief Financial Officer | Sold (plan)Aug 4 | 4,761 shat $24.36 · $116K |
From Form 4 filings with the SEC. Open-market trades only. "Plan" = a sale set up in advance under a 10b5-1 plan, usually routine.
Not financial advice. Research and education only: the same view for everyone, with no regard to your circumstances. Past results do not predict future ones. Decide for yourself or with a licensed adviser. Terms · Privacy